Cardiol Therapeutics Comments on the Descheduling of Purisys Cannabinoid Ingredients by U.S. Drug Enforcement Agency

0
2

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF), a leader in the production of pharmaceutical cannabidiol (“CBD”) products and in the development of innovative cannabidiol medicines for heart disease, commented on Purisys, LLC’s news release issued on November 21st which states that the U.S. Drug Enforcement Agency (“DEA”) has removed their cannabinoid ingredients from Schedule I […]

The post Cardiol Therapeutics Comments on the Descheduling of Purisys Cannabinoid Ingredients by U.S. Drug Enforcement Agency appeared first on Technical420.